Alcyone Lifesciences was founded in 2010 to address the unmet needs in treatment of chronic neuropathological conditions. We are committed to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from these chronic conditions.
We are a team of scientists, engineers, administrators and businesspeople dedicated to building a world-class company that improves the lives of the millions of patients worldwide coping with chronic neurological disorders.
Through innovation, a commitment to excellence, and strong key partnerships, we develop tailored solutions to address treatments of complex CNS disorders.
Alcyone Lifesciences, Inc. was founded to address the unmet needs in treatment of chronic neuropathological conditions.
Alcyone assembles world-class scientific advisory board.
Alcyone begins development on its innovative Alcyone MEMS Cannula(AMC).
Alcyone begins collaboration with Boston Children's Hospital to address the preeminent problem in Hydrocephalus treatment - ventricular shunt occlusion.
Alcyone MEMS Cannula (AMC) pivotal proof of concept.
Preclinical signal for the ReFlow™ CSF management system.
Alcyone receives FDA clearance for the Alcyone MEMS Cannula (AMC).
Preclinical development of Pulsar for intrathecal delivery.
Alcyone successfully demonstrates its AMC platform application in GBM oncolytic viral therapy.
Alcyone files 510(k) premarket notification for the ReFlow™ Ventricular System.
Alcyone plans to spin off Anuncia, Inc., a patient-centric company solely focused on the treatment of Hydrocephalus, with ReFlow™ as its first product. Learn More
*The Alcyone MEMS Cannula (AMC™) System, a neuro-ventricular cannula, has US Food and Drug Administration (FDA) 510(k) clearance, Health Canada Licensing, and CE Marking. It is indicated for use in the U.S. and Canada for the injection of Cytarabine or the removal of cerebrospinal fluid from the ventricles of the brain during an intracranial procedure, and approved in Europe for injection or removal of substances from the brain and/or ventricles of the brain during intracranial procedures. The AMC is a dual-lumen, MR-compatible injection and aspiration cannula and can be used with existing commercial imaging and stereotactic systems. The AMC is not intended for implant, and it is intended for single patient use only.
** The Pulsar System is not yet available for commercial use and has not yet been cleared by the FDA.
*** The ReFlow™ Ventricular System is not available for commercial use. The ReFlow™ Ventricular System is pending 510(k) clearance from the U.S. Food and Drug Administration, and CE Marking.